Novel Biotechnology Inc.

Published purpose

Novel NBx Platform significantly improves productivity in plasmid DNA manufacturing, securing patents for engineered bacteria. Beyond enhancing productivity, this organism produces higher-quality material with fewer host-related impurities, benefiting various bio-based products, especially protein-based ones like growth factors. The Human Growth Factor market, relying on E.coli, faces challenges of low yields and batch failures. Novel's bacteria demonstrates lower endotoxin production and up to 20X productivity in plasmid DNA manufacturing compared to E.coli. Building on this success, Novel aims to create a disruptive manufacturing platform for EGF and FGF growth factors, anticipating these advantages will transfer to other bioproducts.